Another integrates anti-VEGF therapies with immune checkpoint inhibitors (ICIs), such as anti-PD-1/PD-L1 therapies, where tumor vessel normalization enhances immune cell infiltration.351 Consequently, FDA-approved regimens include atezolizumab (anti-PD-L1 Ab) plus bevacizumab for HCC,685 pembrolizumab (anti-PD-1 Ab) plus axitinib (TKI) for renal cell carcinoma,686 and atezolizumab (anti-PD-L1 Ab) plus bevacizumab (anti-VEGF-A Ab) with chemotherapy for NSCLC.687 Yet, efforts persist to optimize patient selection and minimize toxicity.688,689. This evidence concerns the gene CD274 and hereditary clear cell renal cell carcinoma.